share_log

Hims & Hers Health | 8-K: Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results

Hims & Hers Health | 8-K: Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results

Hims & Hers Health | 8-K:Hims & Hers Health, Inc. 公布2024年第二季度财务业绩
美股SEC公告 ·  2024/08/05 16:15

Moomoo AI 已提取核心信息

Hims & Hers Health delivered exceptional Q2 2024 performance with revenue reaching $315.6 million, up 52% YoY, driven by strong subscriber growth to 1.9 million users. The company achieved significant profitability milestones with net income of $13.3 million, compared to a $7.2 million loss in Q2 2023, while Adjusted EBITDA grew to $39.3 million.The company demonstrated robust operational efficiency with gross margin at 81% and marketing expenses decreasing from 51% to 46% of revenue YoY. Free cash flow surged 377% YoY to $47.6 million, while maintaining a strong balance sheet with $227 million in cash and investments with no debt.Looking ahead, Hims & Hers raised its full-year 2024 guidance to $1.37-$1.40 billion in revenue and $140-$155 million in Adjusted EBITDA. The company also announced a new $100 million share repurchase program, reflecting confidence in its growth trajectory and commitment to delivering shareholder value.
Hims & Hers Health delivered exceptional Q2 2024 performance with revenue reaching $315.6 million, up 52% YoY, driven by strong subscriber growth to 1.9 million users. The company achieved significant profitability milestones with net income of $13.3 million, compared to a $7.2 million loss in Q2 2023, while Adjusted EBITDA grew to $39.3 million.The company demonstrated robust operational efficiency with gross margin at 81% and marketing expenses decreasing from 51% to 46% of revenue YoY. Free cash flow surged 377% YoY to $47.6 million, while maintaining a strong balance sheet with $227 million in cash and investments with no debt.Looking ahead, Hims & Hers raised its full-year 2024 guidance to $1.37-$1.40 billion in revenue and $140-$155 million in Adjusted EBITDA. The company also announced a new $100 million share repurchase program, reflecting confidence in its growth trajectory and commitment to delivering shareholder value.
Hims & Hers Health在2024年第二季度表现出色,营业收入达到31560万美元,同比增长52%,这得益于用户数增加至190万。公司实现了显著的盈利里程碑,净利润为1330万美元,而2023年第二季度则亏损720万美元,调整后的息税折旧摊销前利润(EBITDA)增长至3930万美元。公司展现出强大的运营效率,毛利率为81%,营销费用同比从收入的51%降至46%。自由现金流同比激增377%,达到4760万美元,同时保持强劲的资产负债表,现金及投资总额为22700万美元,且无负债。展望未来,Hims & Hers将2024全年指引上调至营业收入为13.7亿至14亿美元,调整后EBITDA为1.4亿至15500万美元。公司还宣布了一项新的10000万美元股票回购计划,反映了对其增长轨迹的信心以及对股东价值的承诺。
Hims & Hers Health在2024年第二季度表现出色,营业收入达到31560万美元,同比增长52%,这得益于用户数增加至190万。公司实现了显著的盈利里程碑,净利润为1330万美元,而2023年第二季度则亏损720万美元,调整后的息税折旧摊销前利润(EBITDA)增长至3930万美元。公司展现出强大的运营效率,毛利率为81%,营销费用同比从收入的51%降至46%。自由现金流同比激增377%,达到4760万美元,同时保持强劲的资产负债表,现金及投资总额为22700万美元,且无负债。展望未来,Hims & Hers将2024全年指引上调至营业收入为13.7亿至14亿美元,调整后EBITDA为1.4亿至15500万美元。公司还宣布了一项新的10000万美元股票回购计划,反映了对其增长轨迹的信心以及对股东价值的承诺。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息